Total pancreatectomy for primary pancreatic neoplasms: Renaissance of an unpopular operation

Annals of Surgery

Volumn 261, Issue 3, 2015, Pages 537-546

  Hartwig, Werner ^a   Gluth, Alexander ^a   Hinz, Ulf ^a   Bergmann, Frank ^a   Spronk, Pauline E R ^a   Hackert, Thilo ^a   Werner, Jens ^a   Büchler, Markus W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adenocarcinoma; Extended; Morbidity; Pancreas; Prognosis; Resection; Surgery

Indexed keywords

ALPHA TOCOPHEROL; HEMOGLOBIN A1C; RETINOL; BIOLOGICAL MARKER;

ADULT; AGED; CANCER SURGERY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OPERATION DURATION; OPERATIVE BLOOD LOSS; PANCREAS RESECTION; PANCREAS TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SURGICAL MORTALITY; VITAMIN BLOOD LEVEL; BLOOD; EPIDEMIOLOGY; GERMANY; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PROCEDURES; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; FEMALE; GERMANY; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84927116633     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000791     Document Type: Conference Paper

References (39)

1. Hartwig W, Werner J, Jager D, et al. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14: E476-e485.
2. ReMine WH, Priestley JT, Judd ES, et al. Total pancreatectomy. Ann Surg. 1970;172: 595-604.
3. Schmidt CM, Glant J, Winter JM, et al. Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma. Surgery. 2007;142: 572-578.
4. Janot MS, Belyaev O, Kersting S, et al. Indications and early outcomes for total pancreatectomy at a high-volume pancreas center. HPB Surg. 2010; 2010 pii: 686702.
5. Dresler CM, Fortner JG, McDermott K, et al. Metabolic consequences of (regional) total pancreatectomy. Ann Surg. 1991;214: 131-140.
6. Billings BJ, Christein JD, Harmsen WS, et al. Quality-of-life after total pancreatectomy: Is it really that bad on long-term follow-up? J Gastrointest Surg. 2005;9: 1059-1066.
7. Müller MW, Friess H, Kleeff J, et al. Is there still a role for total pancreatectomy? Ann Surg. 2007;246: 966-974.
8. Belyaev O, Herzog T, Chromik AM, et al. Early and late postoperative changes in the quality of life after pancreatic surgery. Langenbecks Arch Surg. 2013;398: 547-555.
9. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. N Engl J Med. 2009;361: 1368-1375.
10. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364: 2128-2137.
11. Lemmens VE, Bosscha K, van der SchellingG, et al. Improving outcome for patients with pancreatic cancer through centralization. Br J Surg. 2011;98: 1455-1462.
12. Reddy S, Wolfgang CL, Cameron JL, et al. Total pancreatectomy for pancreatic adenocarcinoma: Evaluation of morbidity and long-term survival. Ann Surg. 2009;250: 282-287.
13. Crippa S, Tamburrino D, Partelli S, et al. Total pancreatectomy: Indications, different timing, and perioperative and long-term outcomes. Surgery. 2011;149: 79-86.
14. Werner J, Fritz S, Büchler MW. Intraductal papillary mucinous neoplasms of the pancreas-A surgical disease. Nat Rev Gastroenterol Hepatol. 2012;9: 253-259.
15. Kulu Y, Schmied BM, Werner J, et al. Total pancreatectomy for pancreatic cancer: Indications and operative technique. HPB (Oxford). 2009;11: 469-475.
16. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. New York, NY: Springer; 2010.
17. Verbeke CS, Leitch D, Menon KV, et al. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93: 1232-1237.
18. Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15: 1651-1660.
19. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 2001;37: 1345-1351.
20. Hartwig W, Vollmer CM, Jr, Fingerhut A, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: Definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery. 2014;156: 1-14.
21. Heidt DG, Burant C, Simeone DM. Total pancreatectomy: Indications, operative technique, and postoperative sequelae. J Gastrointest Surg. 2007;11: 209-216.
22. Cameron JL, Riall TS, Coleman J, et al J. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244: 10-15.
23. Hartwig W, Hackert T, Hinz U, et al. Multivisceral resection for pancreatic malignancies: Risk-analysis and long-term outcome. Ann Surg. 2009;250: 81-87.
24. Burdelski CM, Reeh M, Bogoevski D, et al.Multivisceral resections in pancreatic cancer: Identification of risk factors. World J Surg. 2011;35: 2756-2763.
25. Mollberg N, Rahbari NN, Koch M, et al. Arterial resection during pancreatectomy for pancreatic cancer: A systematic review and meta-analysis. Ann Surg. 2011;254: 882-893.
26. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA. 2013;310: 1473-1481.
27. Neoptolemos JP, Stocken DD, Bassi C, et al.Adjuvant chemotherapywith fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 2010;304: 1073-1081.
28. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364: 1817-1825.
29. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008;19: 1592-1599.
30. Chua TC, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: A systematic review. J Gastrointest Surg. 2010;14: 1442-1452.
31. Zhou Y, Zhang Z, Liu Y, et al. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: A meta-analysis. World J Surg. 2012;36: 884-891.
32. Nakao A, Kanzaki A, Fujii T, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg. 2012;255: 103-108.
33. Campbell F, Foulis AK, Verbeke CS. Dataset for the histopathologic reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. Available at: Http://www.rcpath.org. Published May 2010. Accessed 2010.
34. Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: Better prediction of outcome. Ann Surg. 2011;254: 311-319.
35. Konstantinidis IT, Warshaw AL, Allen JN, et al. Pancreatic ductal adenocarcinoma: Is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013;257: 731-736.
36. Jamieson NB, Foulis AK, Oien KA, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010;251: 1003-1010.
37. Jamil LH, Chindris AM, Gill KR, et al. Glycemic control after total pancreatectomy for intraductal papillary mucinous neoplasm: An exploratory study. HPB Surg. 2012;2012: 381328.
38. Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24: 2897-2902.
39. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: Perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20: 2188-2196.